Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as ...

Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in ...

B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

The MPN Research Foundation, a respected and influential member of the myeloproliferative neoplasms landscape, has two ...

Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533 ZURICH-SCHLIEREN, ...

Rose Leaf Ragtime Club: Monthly meeting of ragtime era music, 1 p.m. Dec. 14. Non-members of the club, $5 donation. Food and ...

North Vancouver arts organization gets major boost thanks to funding from the estate of artist Ann Kipling and the Audain ...

LOUISVILLE, Ky. — The Kentucky Exposition Center will host a car show this weekend, benefitting victims of the UPS plane ...

AMESA announces it has been selected by AFWERX for a Direct-to-Phase II SBIR contract, in the amount of $1.25 million, focused on advancing its multi-agent AI wargaming platform to support strategic ...